Triple-Agonist Metabolic Research Peptide
Retatrutide, development code LY3437943, is a synthetic 39-residue triple agonist peptide developed to target the GIP, GLP-1 and glucagon receptors simultaneously. Supplied as lyophilised powder for laboratory research and studied in receptor pharmacology and metabolic research models. Independently tested by Janoshik Analytical — the batch reports for 10mg (PLB-003) and 20mg (PLB-002) are on our Lab Reports page.
59.99
Inc. VAT · Free UK delivery over £75
Janoshik Analytical · 10mg: 99.515% purity, 13.51mg measured · 20mg: 99.763% purity, 18.36mg measured
About Retatrutide
Retatrutide is a synthetic 39-residue peptide engineered as a triple hormone receptor agonist, simultaneously activating the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. Published research literature refers to it by its Eli Lilly development code, LY3437943, or by the name retatrutide. Pureline lists it under the internal product code RT1.
The published research on retatrutide, including the limits of what it shows and its investigational status, is reviewed on our Retatrutide compound profile. Retatrutide is not authorised as a medicine in the United Kingdom.
All Pureline Biolabs retatrutide is supplied as a lyophilised powder in sealed vials.
Product Specifications
| Compound | Retatrutide |
| Research name | Retatrutide |
| Classification | Triple agonist (GIP/GLP-1/Glucagon) |
| Amino acids | 39 |
| Molecular weight | ~4731.5 g/mol |
| Vial sizes | 10mg / 20mg nominal, lyophilised powder |
| Measured content | 10mg vial: 13.51mg · 20mg vial: 18.36mg |
| Purity | 10mg: 99.515% · 20mg: 99.763% — Janoshik verified |
| Form | Lyophilised powder, sealed vial |
| Batch | 10mg: PLB-003, Janoshik task #226521 · 20mg: PLB-002, task #226522 |
| Research use only | Not for human consumption |
Research Background
Retatrutide (LY3437943) has been studied in receptor pharmacology and metabolic research. The areas below describe what studies measured, not established effects. For the full evidence review, see the Retatrutide compound profile. This product is supplied for laboratory research purposes only.
Animal studies have measured energy expenditure and thermogenesis markers.
Rodent diet-induced obesity models have used fat mass and lean mass measurements as endpoints.
Studies have measured glucose tolerance and insulin signalling markers.
Animal studies have measured food intake and hypothalamic signalling markers.
Studies have measured the contribution of glucagon-receptor activity within the triple-agonist mechanism.
Studies have compared receptor activity against single- and dual-agonist incretin peptides.
Store in refrigerator. Keep away from direct light and heat sources.
Use within 28 days. Do not refreeze once reconstituted.
Stable for up to 24 months when frozen as lyophilised powder.
Standard refrigerator storage conditions are sufficient. Protect from prolonged direct light.
Reconstitution Guide
Retatrutide is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use in research applications.
Allow vial to reach room temperature. Clean the rubber stopper with an alcohol swab and allow to dry completely.
Draw required volume of BAC water into a sterile syringe. Inject slowly down the inside of the vial wall — not directly onto the powder.
Gently swirl until powder fully dissolves. Do not shake. Solution should be clear and colourless.
Use our Reconstitution Calculator → for exact volumes.
Customer Reviews
1 review for Retatrutide 10mg / 20mg UK
All products sold by Pureline Biolabs Ltd are intended strictly for laboratory research purposes only. Not approved for human consumption, veterinary use, or any other application. Not evaluated by the MHRA or any other regulatory authority. Pureline Biolabs Ltd · Company No. 17236739 · purelinebiolabs.com
Lauren (verified owner) –
Great product. QR code on the label to see the testing